ArticleEuropean journal of epidemiology2025
Associations of serum iron and its status change with mortality risk: prospective findings from the MJ cohort.
Article in European journal of epidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Iron status from diet and serum in relation to biological aging acceleration: A NHANES cross-sectional study.Asia Pacific journal of clinical nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Previous studies on serum iron levels and mortality risk have yielded inconsistent findings based on single-point measurements. How serum iron levels and their longitudinal changes influence all-cause and cause-specific mortality remains unknown. This study investigated associations between baseline serum iron levels, their longitudinal changes, and all-cause and cause-specific mortality in a prospective cohort. Participants were recruited from the Taiwan MJ cohort (1997-2007) and followed until December 31, 2022. Baseline serum iron was categorized as low, normal, or high. Based on changes at a second visit, participants were further classified as persistent normal, progression to abnormal, reversion to normal, or persistent abnormal. Cox proportional hazard models were used for analysis. Over a median follow-up of 19.0 years, 33,005 deaths occurred. Fully adjusted models demonstrated J-shaped associations between serum iron and all-cause and cause-specific mortality (all P < 0.001), with higher all-cause mortality risks in low (HR 1.27, 95% CI [1.23, 1.31]) and high iron groups (HR 1.37, 95% CI [1.30, 1.44]). Compared to persistent normal levels, those with progression to abnormal, reversion to normal, or persistent abnormal serum iron exhibited elevated mortality risks (HRs: 1.22 [1.15, 1.30], 1.16 [1.09, 1.24], 1.49 [1.36, 1.63], respectively). Moreover, maintaining normal serum iron status alongside a healthy lifestyle exhibited the lowest mortality risks. Long term abnormal serum iron status was linked to increased mortality, which could be mitigated through lifestyle modifications, suggesting significance of serum iron monitoring and potential intervention.
Indexed as
Identifiers
40888985What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.